Clinical Trial Study About Human Adipose-Derived Stem Cells in the Liver Cirrhosis

Study Overview
=================
Brief Summary
-----------------
The aim of the investigators study was to investigate the safety and efficacy of autologous ADSCs for the clinical treatment of liver cirrhosis.

Detailed Description
-----------------
One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.

Official Title
-----------------
Adipose-Derived Stem Cells (ADSCs) Injections for Liver Cirrhosis

Conditions
-----------------
Liver Cirrhosis

Intervention / Treatment
-----------------
* Drug: ADSCs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Liver cirrhosis investigators with age 20 to 80 years (both inclusive). Investigators without Mandatory Communicable Disease (HBV, HCV, HIV, syphilis) Investigators without rare disorder Coagulation normalities Investigators without autoimmune disorder Investigators without Acquired Immune Deficiency Syndrome Investigators without cancer Investigators BMI > 15 Exclusion Criteria: Pregnant women Investigators with acute stroke in one month and unconsciousness Investigators with acute myocardial infarction or acute heart failure Investigators with serious liver dysfunction and coagulation dysfunction and ascites mild higher Investigators with acute respiratory failure or pneumonia Kidney Failure: BUN > 50 Anemia: Hematocrit < 25 Investigators diagnosed with liver cancer or liver metastatic carcinoma Investigators with liver abscess Investigators with acute Hepatitis Investigators with acute infective Liver cirrhosis patients with HBV or HCV Investigators diagnosed with carcinoma and receiving treatment Investigators with Schizophrenia or melancholia Investigators received serious surgical operations in 3 months Investigators unable to control hypertension (SBP > 180 mmHg, DBP > 110 mmHg) or diabetes (AC sugar > 200 mg/dl) Others can't fit into the trial evaluate by investigator

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ADSCs<br>One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle. | Drug: ADSCs<br>* autologous ADSCs<br>* Other names: hADSCs;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MELD | MELD uses the patient's values for serum bilirubin, serum creatinine, and the international normalized ratio for prothrombin time (INR) to predict survival. It is calculated according to the following formula:MELD = 3.78[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.57[Ln serum creatinine (mg/dL)] + 6.43. | 1-6 month |